(MENAFN- The Peninsula) The Peninsula
A research team headed by Dr Omar El-Agnaf (pictured), Acting Executive Director of Qatar Biomedical Research Institute (QBRI), has been selected by the Austrian biotechnology company, AFFiRiS AG, to evaluate selected parameters in clinical trials on an innovative approach to treating Parkinson's disease that has been developed by the company.
QBRI is one of Hamad Bin Khalifa University's (HBKU) three national research institutes.
A research carried out by Dr El-Agnaf's team of scientists that uses novel techniques to identify biomarkers of Parkinson's disease in human blood and cerebral spinal fluid samples attracted the attention of AFFiRiS AG. The Austrian company is a leader in the field of developing immunotherapies that target chronic diseases with unmet medical needs.
This led them to call upon the Qatar-based team to use the tools and expertise developed at HBKU to validate the target engagement of alpha-synuclein for the company's first-of-its-kind Parkinson's disease anti-alpha-synuclein immunotherapy approach.
The product has been developed in Europe by a team of scientists and its pre-clinical and clinical development has been supported by Michael J. Fox Foundation.
Using the team's novel analysis techniques, the researchers at HBKU will assess the product's ability to engage with the target, alpha-synuclein. QBRI's scientists will explore novel biomarkers discovered by them that facilitate early diagnosis and treatment of Parkinson's disease and use the technique they have developed at HBKU to assess the magnitude of target engagement of this new immunotherapy-based compound.
MENAFN2504201700630000ID1095419230
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.